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Lithium-induced Drug Reaction with Eosinophilia and Systemic Symptom Syndrome

Anupama Bains
From Sir, Drug reaction with eosinophilia and systemic symptoms (DRESS) is one of the severe cutaneous adverse drug reactions characterized by rash and systemic organ involvement. The term DRESS syndrome was coined by Bocquet et al. in 1996 , which describes all the components of the syndrome. [1] Aromatic group of anticonvulsants, i.e., phenytoin, phenobarbitone, carbamazepine, lamotrigine, dapsone, sulphasalazine, and allopurinol are the common causes of DRESS syndrome. [2] There are only a few case reports of DRESS syndrome secondary to lithium in literature.
A 40-year-old female presented to the dermatology outpatient department with a complaint of rash over the whole body for last 7 days which was associated with intense pruritus. The patient was a known case of bipolar disorder and was on lithium, lamotrigine, mirtazapine, amisulpride, and trihexyphenidyl from a private practitioner. The patient developed rash after 3½ weeks of drug intake. Except for lithium and lamotrigine, the patient had taken other mentioned drugs in past also without any history of rash. On examination, she was febrile and had facial, pedal edema. There was no lymphadenopathy. Cutaneous examination revealed generalized erythematous urticated maculopapular rash with scaling. Rash was more pronounced on face, trunk, and upper limbs [ Figure 1 ]. Rest of examination was within normal limits. Complete hemogram revealed hemoglobin 9.8 g, total leukocyte count 15,400/mm 3 , and absolute eosinophil count of 1100/μl. Peripheral smear showed microcytic, hypochromic anemia with neutrophilic leukocytosis. There was a slight increase in liver enzymes with serum glutamic oxaloacetic transaminase 45 (<35) U/L and serum glutamic pyruvic transaminase 57 (<35) U/L. Rest of routine investigations were within normal limits. Since the patient had a long latent period between the intake of drug and onset of rash, urticated papular exanthem, facial edema, fever, eosinophilia, leukocytosis, and raised liver enzymes, the patient was diagnosed as a possible case of DRESS syndrome according to RegiSCAR (European Registry of Severe Cutaneous Adverse Reaction) criteria. [3] Culprit drug was thought to be lamotrigine as aromatic group of drugs cause DRESS more frequently. All medicines were stopped and the patient was started on oral steroids as 1 mg/kg body weight which was then tapered gradually over a period of 6 weeks along with antihistamines. There was subsidence of rash with normalization of liver function tests and absolute eosinophil count. After 2 weeks, the patient again visited the same psychiatrist. This time, lamotrigine was avoided, and the patient was again put on lithium. After 3 days, the patient developed similar rash with facial edema. This time, liver function tests were normal, but total leukocyte count was 14,900/mm 3 and absolute eosinophil count 1300/μl. On reexposure to lithium, patient developed similar episode within a short time interval. Hence, the diagnosis was changed to DRESS syndrome secondary to lithium. The patient was started on oral steroids which were gradually tapered in 4 weeks and antihistamines. This was followed by improvement in rash and normalization of counts.
Shreedhar et al. also described a patient of DRESS syndrome secondary to lithium. [4] Although aromatic group of anticonvulsants are the main culprits in DRESS syndrome, possibility of DRESS syndrome secondary to lithium should also be kept in mind because early withdrawal of the offending drug may avoid a life-threatening complication.
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